Page last updated: 2024-11-06

bromerguride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Bromerguride is a dopamine agonist and ergot derivative that has been used in the treatment of Parkinson's disease, hyperprolactinemia, and other conditions. It is synthesized through a multi-step process involving the modification of ergot alkaloids. Bromerguride has been shown to exert its effects by stimulating dopamine receptors in the brain, leading to a variety of physiological responses. Its importance lies in its potential therapeutic applications, particularly in the management of neurological and endocrine disorders. Research on bromerguride continues to explore its efficacy, safety, and potential for new therapeutic indications. The study of bromerguride is driven by its unique pharmacological profile and its potential to address a range of medical conditions.'

bromerguride: dopamine antagonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71266
CHEMBL ID2104211
SCHEMBL ID678238
MeSH IDM0118623

Synonyms (21)

Synonym
bromerguride
zk-95451
2-br-lis
83455-48-5
bromerguridum
3-(2-bromo-9,10-didehydro-6-methylergolin-8alpha-yl)-1,1-diethylurea
bromergurida [spanish]
bromerguridum [latin]
hx58m2377w ,
bromerguride [inn]
unii-hx58m2377w
bromergurida
CHEMBL2104211
3-(2-bromo-9,10-didehydro-6-methylergolin-8.alpha.-yl)-1,1-diethylurea
SCHEMBL678238
DTXSID70232356
3-(2-bromo-9,10-didehydro-6-methyl-8alpha-ergolinyl)-1,1-diethylurea
SBHNNNRQZGYOAU-YVEFUNNKSA-N
Q27280141
3-[(6ar,9s)-5-bromo-7-methyl-6,6a,8,9-tetrahydro-4h-indolo[4,3-fg]quinolin-9-yl]-1,1-diethylurea
AKOS040748060

Research Excerpts

Overview

Bromerguride is a novel dopamine antagonistic ergot derivative. It has a reversed pharmacodynamic profile.

ExcerptReferenceRelevance
"Bromerguride is a novel dopamine antagonistic ergot derivative in which a complete reversed pharmacodynamic profile has been obtained by bromine substitution at position 2 as compared to dopamine agonistic lisuride. "( Pharmacokinetics of bromerguride, a new dopamine-antagonistic ergot derivative in rat and dog.
Hilderbrand, M; Hümpel, M; Krause, W; Täuber, U,
)
1.9

Pharmacokinetics

ExcerptReferenceRelevance
"Bromerguride is a novel dopamine antagonistic ergot derivative in which a complete reversed pharmacodynamic profile has been obtained by bromine substitution at position 2 as compared to dopamine agonistic lisuride."( Pharmacokinetics of bromerguride, a new dopamine-antagonistic ergot derivative in rat and dog.
Hilderbrand, M; Hümpel, M; Krause, W; Täuber, U,
)
1.9

Bioavailability

ExcerptReferenceRelevance
" Because of incomplete absorption the oral bioavailability was approx."( Pharmacokinetics of bromerguride, a new dopamine-antagonistic ergot derivative in rat and dog.
Hilderbrand, M; Hümpel, M; Krause, W; Täuber, U,
)
0.45
" The bioavailability of oral bromerguride was 29% after 1 mg and 25% after 2 mg."( Pharmacokinetics and pharmacodynamics in man of the dopamine antagonist ergot derivative, bromerguride.
Gräf, KJ; Krause, W; Sauerbrey, N, 1986
)
0.78

Dosage Studied

ExcerptRelevanceReference
" dosing of 5 mg/kg (R)."( Pharmacokinetics of bromerguride, a new dopamine-antagonistic ergot derivative in rat and dog.
Hilderbrand, M; Hümpel, M; Krause, W; Täuber, U,
)
0.45
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (38.46)18.7374
1990's7 (53.85)18.2507
2000's1 (7.69)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.55 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]